Generic Name:
dupilumab
Project Status:
Pending
Therapeutic Area:
Atopic dermatitis, pediatrics
Manufacturer:
Sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0774-000
Call for patient/clinician input closed:
Details
Manufacturer Requested Reimbursement Criteria1:
Treatment of patients aged 6 months to 12 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable, as per the Health Canada indication.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab can be used with or without topical corticosteroids.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.